ProPhase Labs Reports Financial Results
for the First Quarter Ended March 31, 2013
DOYLESTOWN, Pennsylvania – May 6, 2013. ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today reported a net sales increase of 25.3% to $7.5 million for the three months ended March 31, 2013 as compared to net sales of $6.0 million for the three months ended March 31, 2012.
The Company realized net income for the three months ended March 31, 2013, of $290,000, or $0.02 per share, compared to a net loss of $688,000, or ($0.05) per share, for the three months ended March 31, 2012. The improved financial results for the three months ended March 31, 2013 as compared to three months ended March 31, 2012 was due principally to increased revenues while the Company maintained comparable operating expenses from period to period.
Ted Karkus, ProPhase Labs' Chairman and CEO stated, “Much like in 2012, our goal going forward is to introduce new Cold-EEZE® branded products which efficiently leverage our marketing dollars and leverage our strengthening distribution platform. As previously articulated, our next generation of Cold-EEZE® products (which we expect to be on shelves in the fall of 2013) will not be new flavors of lozenges but rather Cold-EEZE® products in new delivery forms that shorten the duration of the common cold as well as provide additional health benefits. As evidenced in our most recent financial results, we continue to make excellent progress toward our long term strategy of increasing the value of the Cold-EEZE Cold Remedy brand and the value of our Company to the benefit of all shareholders.”
About ProPhase Labs
ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® Cold Remedy brand as well as other cold relief products. Cold-EEZE® zinc gluconate lozenges are clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC (“Phusion”). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase’s robust over-the-counter distribution channels. For more information visit us at www.ProPhaseLabs.com.
Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.
| Press Only Contact | Investor Contact | |
| Laura Maxey | Ted Karkus, Chairman and CEO | |
| 5W Public Relations | ProPhase Labs, Inc. | |
| Tel: (212) 452-6400 | (215) 345-0919 x 0 | |
| lmaxey@5wpr.com |
PROPHASE LABS, INC. & SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended March 31, | ||||||||
| 2013 | 2012 | |||||||
| Net sales | $ | 7,542 | $ | 6,018 | ||||
| Cost of sales | 2,203 | 1,678 | ||||||
| Gross profit | 5,339 | 4,340 | ||||||
| Operating expenses: | ||||||||
| Sales and marketing | 3,363 | 3,177 | ||||||
| Administrative | 1,498 | 1,492 | ||||||
| Research and development | 188 | 361 | ||||||
| 5,049 | 5,030 | |||||||
| Income (loss) from operations | 290 | (690 | ) | |||||
| Interest and other income | - | 2 | ||||||
| Income (loss) before income taxes | 290 | (688 | ) | |||||
| Income tax (benefit) | - | - | ||||||
| Net Income (loss) | $ | 290 | $ | (688 | ) | |||
| Basic income (loss) per share: | ||||||||
| Net income (loss) | $ | 0.02 | $ | (0.05 | ) | |||
| Diluted income (loss) per share: | ||||||||
| Net income (loss) | $ | 0.02 | $ | (0.05 | ) | |||
| Weighted average common shares outstanding: | ||||||||
| Basic | 15,752 | 14,796 | ||||||
| Diluted | 16,199 | 14,796 | ||||||
PROPHASE LABS, INC. & SUBSIDIARIES
CONSOLIDATED BALANCE SHEET DATA
(in thousands)
(unaudited)
| March 31, | December 31, | |||||||
| 2013 | 2012 | |||||||
| Cash and cash equivalents | $ | 4,536 | $ | 572 | ||||
| Accounts receivable | $ | 3,080 | $ | 5,409 | ||||
| Inventory | $ | 2,147 | $ | 2,051 | ||||
| Total current assets | $ | 10,251 | $ | 10,719 | ||||
| Total assets | $ | 16,139 | $ | 16,661 | ||||
| Total current liabilities | $ | 3,864 | $ | 4,910 | ||||
| Other long term obligations | $ | 300 | $ | 300 | ||||
| Total stockholders' equity | $ | 11,975 | $ | 11,451 | ||||